Please assess the completion status of the following clinical trial:

Trial Title: Thiazolidinedione Intervention With Vitamin D Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women with: a) newly detected type 2 diabetes based on a fasting plasma glucose greater than or equal to 7.0 mmol/l (126 mg/dL) or a 2 hour plasma glucose (FPG) greater than or equal to 11.1 mmol/l (200 mg/dL) on an oral glucose tolerance test, or b) a history of type 2 diabetes~* Hemoglobin A1c (A1C) 6.5-9.5% inclusive (for assays with upper limit of normal of 6%) within one month of screening~* Age ≥ 50 years and evidence of vascular disease defined as ≥1of:~  * prior myocardial infarction~ * prior stroke~ * coronary, carotid or peripheral artery revascularization ≥ 4 years earlier~ * previous documented myocardial ischemia on either an exercise stress test or on any cardiac imaging, or previous unstable angina with ECG changes or cardiac enzyme elevation OR~* Age ≥ 55 years and evidence of subclinical vascular disease defined as ≥1 of:~  * microalbuminuria or proteinuria~ * history of treated or untreated hypertension with left ventricular hypertrophy by electrocardiogram (ECG) or echocardiogram~    * 50% stenosis on any imaging of coronary, carotid or lower extremity arteries~ * ankle/brachial index \<0.9 OR~* Age ≥ 60 years and at least 2 of the following cardiovascular disease risk factors:~  * current tobacco use~ * LDL-c ≥3.4 mmol/L (130 mg/dL) or on a lipid lowering medication~ * HDL-c \< 1.0 mmol/L (40 mg/dL) for men and \< 1.3 mmol/L (50 mg/dL) for women or triglycerides ≥ 2.3 mmol/L (200 mg/dL)~ * BP lowering medication use or untreated SBP ≥ 140 mmHg or DBP ≥ 95 mmHg~ * Waist to hip ratio \> 1.0 for men and \> 0.8 for women~* On no insulin and on less than or equal to 2 anti-diabetes drugs where at least one drug is at or below the half-maximal dose (as indicated in the MOP) with stable dosing for 10 weeks prior to screening~Exclusion Criteria:~* Type 1 diabetes~* Current need for insulin treatment~* Symptomatic hyperglycemia requiring immediate therapy in the judgment of the physician~* An acute cardiovascular event within 30 days prior to randomization~* Symptomatic heart failure (i.e. New York Heart Association class II or higher) or any episode of previous pulmonary edema or known ejection fraction \< 0.4 or current use of loop diuretics~* Any fracture within the past 1 year~* Currently planned coronary, carotid or peripheral artery revascularization or cardiac valve surgery~* Coronary, carotid or peripheral artery revascularization within the 4 years prior to screening in the absence of angina, MI, or stroke in the intervening period~* End stage renal disease requiring renal replacement therapy~* Receiving drug therapy to treat liver disease~* A diagnosis of cancer (other than superficial squamous, basal cell skin cancer, or adequately treated cervical carcinoma in situ) in the past 3 years or current treatment for the active cancer (other than prophylactic)~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level \> 2.5 times the upper limit of normal~* A prior heart transplant or awaiting a heart transplant~* Previous or current hypercalcemia, hyperparathyroidism, osteomalacia or other contraindication for vitamin D therapy~* Regular use of or indication for greater than 400IU of vitamin D daily~* Clinically or medically unstable with expected survival \< 1 year~* Unwillingness to permit sites to contact their primary physicians to communicate information about the study and the participant's data~* Any other factor likely to limit protocol compliance or reporting of adverse events~* Inability to discontinue a TZD (if taking one) in the judgement of the physician/investigator~* Contraindications to or history of hypersensitivity to the investigational products~* History of renal stones within the past 2 years~* Participation in another clinical trial of an investigational agent

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pioglitazone (Type: ACTIVE_COMPARATOR): PIO tablet was administered in the dose of 30 milligrams (mg) OD initially and could be titrated to a maximum dose of 45 mg at or after the 6-month visit. After 1 year of treatment, the dose of PIO was increased to 45 mg OD for the duration of 5.5 years.
- rosiglitazone (Type: ACTIVE_COMPARATOR): RSG tablet was administered in the dose of 4 mg OD initially and could be titrated to a maximum dose of 8 mg at or after the 6-month visit. After 1 year of treatment, the dose of RSG was increased to 8 mg OD for the duration of 5.5 years.
- TZD placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet was administered once a day (OD) for the duration of 5.5 years
- Vitamin D (Type: ACTIVE_COMPARATOR): Active comparator
- Vitamin D placebo (Type: PLACEBO_COMPARATOR): Placebo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).